Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3865)	12/18/1997 8:04:00 AM
From: Zebra 365	Read Replies (2) \| Respond to of 23519

Ireland announcement: VIVUS Ireland Limited and the IDA Ireland Sign Investment Proposal MENLO PARK, Calif.--(BW HealthWire)--Dec. 18, 1997--VIVUS Ireland Limited, a wholly owned subsidiary of VIVUS Inc., (NASDAQ:VVUS), a U.S. pharmaceutical company, and the Irish Development Agency (IDA) completed an investment proposal for the construction of a facility to produce the Company's product MUSE(R) (alprostadil). The proposal calls for the creation of approximately 250 new jobs over three years at the IDA Ireland Navan Business Park, County Meath. MUSE, currently approved for sale in the United States and the United Kingdom, is a transurethral delivery system for the treatment of erectile dysfunction. The product, launched in the U.S. in January 1997, had U.S. sales of over $100 million during the first nine months of 1997. A 30 acre site at the business park has been selected where VIVUS is planning to build a production facility. MUSE produced at the Navan facility will supply product to support distribution agreements VIVUS International has signed with Astra AB and Janssen-Cilag. "This production facility will be the focal point of VIVUS' European presence, playing a central role in supplying our international markets as VIVUS obtains further regulatory approvals outside the United States," said Leland Wilson, President and CEO of VIVUS, Inc. and a Director of VIVUS Ireland. VIVUS Ireland Limited has commenced recruitment of senior management to staff the organization and production facility. General recruitment of production staff is expected to begin prior to the completion of the facility. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive, drug delivery system that delivers pharmacologic agents via the urethra. -0- Note to Editors and Investors: MUSE is a registered trademark of VIVUS Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (888/329-5719). CONTACT: VIVUS Nina W. Ferrari/David Yntema, 415/325-5511 IR@VIVUS.com Btw, if you look at the most recent 10k filing about the Janssen deal, it is interesting that Janssen put in a clause that Vivus would accept Janssen's advice on improving production output if there were problems supplying the demand for the international market. Vivus specifically inserted a clause that barred Janssen from seeking damages if Vivus could not supply them with enough product. Maybe these are typical boilerplate, or maybe the CEO was telling the truth, and the problem is in production capacity and not in demand. Naaaaaaah, the analysts couldn't be wrong. Zebra